Results from a new study indicate that, in elderly multiple myeloma patients, a combination drug regimen of Velcade (bortezomib), melphalan (Alkeran), prednisone, and thalidomide (Thalomid) (VMPT), followed by a maintenance regimen of Velcade and thalidomide, is superior to the current standard treatment of Velcade, melphalan, and prednisone (VMP) without a maintenance regimen. The authors of the study will be presenting the results of the Phase 3 clinical trial at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition.

In the study, scientists randomly assigned…

Preliminary results from an ongoing Phase 2 trial show that a combination therapy of Velcade (bortezomib) and Torisel (temsirolimus) is highly effective in reducing blood and urine levels of abnormal monoclonal protein (known as “M” protein) in multiple myeloma patients. The preliminary study results will be presented at the American Society of Hematology’s (ASH) 51st annual meeting in New Orleans on Monday, December 7.

Myeloma cells produce M proteins. Higher levels of M proteins are directly related to increased disease progression and severity.

Torisel, a drug already approved for…

A new study suggests that Velcade (bortezomib), in combination with other drugs, is a better treatment method for patients with newly diagnosed multiple myeloma than the previous standard drugs.

The study, titled “Velcade, Intravenous Cyclophosphamide, and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial),” will be presented on December 6 at the American Society of Hematology (ASH) Meeting in New Orleans.

The researchers compared a drug cocktail consisting of Velcade, cyclophosphamide (Cytoxan), and dexamethasone (Decadron) with the previous standard cocktail of vincristine,…

At the upcoming meeting of the American Society of Hematology (ASH), there will be several presentations about Actimid (pomalidomide). Actimid, a new drug being developed by Celgene Corporation as a treatment for multiple myeloma, is a molecular derivative of thalidomide (Thalomid).

Actimid As A Combination Therapy With Dexamethasone

One of the ASH presentations will show that the combination regimen of Actimid and low-dose dexamethasone (Decadron) is an effective treatment for relapsed multiple myeloma.

Actimid was tested in combination with dexamethasone in 34 patients with relapsed myeloma following therapy…

The 51st annual meeting of the American Society of Hematology (ASH) kicks off in two weeks in New Orleans. The meeting will feature presentations on the latest in peer-reviewed multiple myeloma research, December 5 through December 8.

ASH annual meetings keep hematologists up to date on research and treatment advances from the past year. According to ASH, the meeting has “a superb educational program,” “cutting-edge scientific sessions,” and presentations that “contain the latest and most exciting developments in scientific research.”

More than 20,000 doctors, scientists, and others from across the…